What is more, the anti-EGFR monoclonal antibody (clone LA1) blocking EGFR has been shown to effectively inhibit in vitro the CD44-mediated aggregation of triple-negative breast cancer cells, reducing metastasis [131]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.